mailed
on 29 Feb 2024
Last Applicant/ Owned by
9880 Campus Point Drive, Suite 210
San Diego
CA
92121
Serial Number
90763884 filed on 09th Jun 2021
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
"BIOSCIENCES"
Providing reagent sample diagnostic testing services for others for scientific research purposes and scientific research related thereto; clinical diagnostic services for scientific research purposes, namely, preparing, amplifying, labeling, detecting, analyzing and sequencing nucleic acids from human beings "BIOSCIENCES" Clinical diagnostic instruments for medical use, namely, nucleic acid sequRead More
Providing reagent sample diagnostic testing services for others for scientific research purposes and scientific research related thereto; clinical diagnostic services for scientific research purposes, namely, preparing, amplifying, labeling, detecting, analyzing and sequencing nucleic acids from human beings
Clinical diagnostic instruments for medical use, namely, nucleic acid sequencers, imaging devices and analyzers, none of the forgoing for use in the veterinary field
Computer systems, namely, computer hardware, downloadable and recorded computer software and associated downloadable data files for collecting, storing, analyzing and reporting biological information, all the foregoing for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; downloadable and recorded computer software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; clinical diagnostic instruments for scientific use, namely, nucleic acid sequencers, imaging devices and analyzers
Medical diagnostic reagents; clinical medical diagnostic reagents; reagent kits and reagent beads with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical medical diagnostic purposes; reagents and reagent kits comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers; all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for diagnostic medical use and for clinical medical use; none of the forgoing for use in the veterinary field
Assays and reagents for use in genetic research; diagnostic reagents for scientific or research use; diagnostic reagents for clinical or medical laboratory use; reagents and reagent kits comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for scientific research use, for diagnostic scientific use, and for clinical laboratory research use; clinical diagnostic reagents for laboratory use; reagent kits and reagent beads with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical diagnostic laboratory purposes
No 90763884
No Service Mark
No ELEM-203
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 29th Feb 2024 | FINAL REFUSAL WRITTEN |
| 29th Feb 2024 | FINAL REFUSAL E-MAILED |
| 29th Feb 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| 26th Jan 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 25th Jan 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 25th Jan 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 26th Oct 2023 | NON-FINAL ACTION WRITTEN |
| 26th Oct 2023 | NON-FINAL ACTION E-MAILED |
| 26th Oct 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 29th Sep 2023 | ASSIGNED TO LIE |
